Characteristics of transmitted drug resistance in treatment-naive HIV-1-infected individuals in Beijing city, 2019-2020
10.3760/cma.j.cn112866-20201019-00269
- VernacularTitle:2019—2020年北京市未治疗HIV-1感染者传播性耐药特征分析
- Author:
Ruolei XIN
1
;
Huihuang HUANG
;
Jia LI
;
Yinxiao HAO
;
Weidong SUN
;
Jie LI
;
Hongyan LU
;
Chun HUANG
Author Information
1. 北京市疾病预防控制中心 北京市预防医学研究中心性病艾滋病防治所 100013
- Keywords:
Human immunodeficiency virus;
Genotypic drug resistance;
Transmitted drug resistance;
Integrase strand transfer inhibitor
- From:
Chinese Journal of Experimental and Clinical Virology
2021;35(4):367-371
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the characteristics of HIV-1 genotypic drug resistance for protease-reverse transcriptase (PR-RT) and integrase (IN) among antiretroviral therapy (ART)-naive individuals in Beijing, and provide evidence for clinical diagnosis and treatment.Methods:Newly diagnosed individuals or cases initiating ART were recruited in Beijing covering 2019 to 2020, then pol gene fragments and integrase gene were synchronously amplified and sequenced. Phylogenetic analyses were performed to determine subtypes, and the pol gene and integrase gene sequences were submitted to Stanford University HIV drug resistance database for the interpretation of mutations and drug resistance. Results:Among 168 ART-naive individuals, 93.6% were infected via men who have sex with men (MSM). The top two subtypes were CRF01_AE (41.0%) and CRF07_BC (30.3%), and unique recombinant forms accounted for 16.1% infections. Six individuals carried surveillance drug resistance mutations in PR-RT, with a prevalence of transmitted drug resistance (TDR) at 3.7%. And one case carried nucleoside reverse transcriptase inhibitor mutation of K65R, accompanied with major integrase mutation of T66I (0.6%), conveying resistance to elvitegravir and raltegravir at high and low levels, respectively.Conclusions:The prevalence of transmitted drug resistance was considerably low among ART-naive individuals in Beijing, and the surveillance of genotypic drug resistance should be strengthened, including integrase drug resistance.
